JP7608425B2 - 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 - Google Patents

線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Download PDF

Info

Publication number
JP7608425B2
JP7608425B2 JP2022501192A JP2022501192A JP7608425B2 JP 7608425 B2 JP7608425 B2 JP 7608425B2 JP 2022501192 A JP2022501192 A JP 2022501192A JP 2022501192 A JP2022501192 A JP 2022501192A JP 7608425 B2 JP7608425 B2 JP 7608425B2
Authority
JP
Japan
Prior art keywords
compound
cancer
disease
pharma
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022501192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541753A (ja
JP2022541753A5 (https=
JPWO2021005125A5 (https=
Inventor
オステルカンプ，フランク
ズボロウスキー，ディルク
シュナイダー，エベラール
ハーセ，クリスチャン
パシュケ，マティアス
ヘーネ，アイリーン
ウンゲウィス，ヤン
スマーリング，クリスチャン
ライニキー，ウルリッチ
ブレーデンベック，アン
Original Assignee
３ベー ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by ３ベー ファーマシューティカルズ ゲーエムベーハー filed Critical ３ベー ファーマシューティカルズ ゲーエムベーハー
Publication of JP2022541753A publication Critical patent/JP2022541753A/ja
Publication of JP2022541753A5 publication Critical patent/JP2022541753A5/ja
Publication of JPWO2021005125A5 publication Critical patent/JPWO2021005125A5/ja
Priority to JP2024221293A priority Critical patent/JP7783396B2/ja
Application granted granted Critical
Publication of JP7608425B2 publication Critical patent/JP7608425B2/ja
Priority to JP2025203677A priority patent/JP2026035703A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022501192A 2019-07-08 2020-07-08 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Active JP7608425B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024221293A JP7783396B2 (ja) 2019-07-08 2024-12-18 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2025203677A JP2026035703A (ja) 2019-07-08 2025-11-26 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19000325.1 2019-07-08
EP19198813.8 2019-09-20
EP19198813 2019-09-20
PCT/EP2020/069298 WO2021005125A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024221293A Division JP7783396B2 (ja) 2019-07-08 2024-12-18 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Publications (4)

Publication Number Publication Date
JP2022541753A JP2022541753A (ja) 2022-09-27
JP2022541753A5 JP2022541753A5 (https=) 2024-04-02
JPWO2021005125A5 JPWO2021005125A5 (https=) 2024-04-02
JP7608425B2 true JP7608425B2 (ja) 2025-01-06

Family

ID=71409439

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022501192A Active JP7608425B2 (ja) 2019-07-08 2020-07-08 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2024221293A Active JP7783396B2 (ja) 2019-07-08 2024-12-18 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2025203677A Pending JP2026035703A (ja) 2019-07-08 2025-11-26 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024221293A Active JP7783396B2 (ja) 2019-07-08 2024-12-18 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2025203677A Pending JP2026035703A (ja) 2019-07-08 2025-11-26 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Country Status (20)

Country Link
US (2) US12427210B2 (https=)
EP (2) EP3997103B9 (https=)
JP (3) JP7608425B2 (https=)
KR (1) KR20220032079A (https=)
CN (3) CN118406106A (https=)
AU (1) AU2020310538B2 (https=)
BR (1) BR112022000122A2 (https=)
CA (1) CA3145340A1 (https=)
CL (1) CL2021003580A1 (https=)
DK (1) DK3997103T3 (https=)
ES (1) ES3012534T3 (https=)
FI (1) FI3997103T3 (https=)
HU (1) HUE070009T2 (https=)
IL (2) IL320543A (https=)
LT (1) LT3997103T (https=)
MX (1) MX2022000252A (https=)
PL (1) PL3997103T3 (https=)
RS (1) RS66480B9 (https=)
SI (1) SI3997103T1 (https=)
WO (1) WO2021005125A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289673B2 (en) * 2019-07-08 2026-04-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
EP4251639A1 (en) * 2020-11-30 2023-10-04 Rayzebio, Inc. Radiopharmaceutical conjugate compositions and uses thereof
US20240139350A1 (en) * 2021-02-01 2024-05-02 Five Eleven Pharma, Inc Radioactively labeled ligand for fibroblast activation protein-alpha imaging agent and preparation method therefor
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
NZ803235A (en) 2021-02-10 2026-01-30 Yantai Lannacheng Biotechnology Co Ltd Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
EP4311557A1 (en) * 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates
JP2025530229A (ja) * 2022-09-07 2025-09-11 ３ベー ファーマシューティカルズ ゲーエムベーハー 前立腺特異的膜抗原（ｐｓｍａ）リガンドおよびその使用
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
WO2024198838A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
KR20260009883A (ko) 2023-05-24 2026-01-20 베이징 창핑 래보러토리 신규 삼관능 화합물 및 이의 용도
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
CN121752300A (zh) 2023-08-31 2026-03-27 荷兰拉德堡德大学学术医学中心 子宫内膜异位症示踪剂
WO2025063849A2 (en) 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
TW202532108A (zh) 2024-02-01 2025-08-16 瑞士商諾華公司 治療癌症的方法
CN121045338A (zh) * 2025-11-05 2025-12-02 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2006042282A2 (en) 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2019083990A2 (en) 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304206A1 (en) 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
EP1943257A2 (en) 2005-05-19 2008-07-16 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CN106794264B (zh) 2014-06-10 2021-03-23 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP3405476B1 (en) 2016-01-20 2022-05-18 Polypeptide Laboratories Holding (PPL) AB METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
WO2017211809A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CN106046121B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
CN105949282B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
IL289673B2 (en) 2019-07-08 2026-04-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
KR20230129261A (ko) 2021-01-07 2023-09-07 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2006042282A2 (en) 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2019083990A2 (en) 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUNN BM et al.，The synthesis, purification, and evaluation of a chromophoric substrate for pepsin and other aspartyl proteases: Design of a substrate based on subsite preferences，Analytical Biochemistry，1984年，vol. 138, no. 1，pp. 68-73

Also Published As

Publication number Publication date
SI3997103T1 (sl) 2025-04-30
HUE070009T2 (hu) 2025-05-28
IL289675A (en) 2022-03-01
EP3997103B1 (en) 2024-11-20
RS66480B9 (sr) 2025-05-30
AU2020310538A1 (en) 2022-01-27
CN118406106A (zh) 2024-07-30
FI3997103T3 (fi) 2025-02-03
BR112022000122A2 (pt) 2022-04-26
ES3012534T3 (en) 2025-04-09
US20260061086A1 (en) 2026-03-05
JP2022541753A (ja) 2022-09-27
JP7783396B2 (ja) 2025-12-09
PL3997103T3 (pl) 2025-03-24
CL2021003580A1 (es) 2022-08-05
EP4517326A3 (en) 2025-05-28
JP2025038131A (ja) 2025-03-18
DK3997103T3 (da) 2024-12-02
EP4517326A2 (en) 2025-03-05
RS66480B1 (sr) 2025-03-31
WO2021005125A1 (en) 2021-01-14
IL320543A (en) 2025-06-01
CN114341159B (zh) 2024-04-26
IL289675B1 (en) 2025-09-01
US20220273831A1 (en) 2022-09-01
US12427210B2 (en) 2025-09-30
JP2026035703A (ja) 2026-03-04
IL289675B2 (en) 2026-01-01
CN114341159A (zh) 2022-04-12
CA3145340A1 (en) 2021-01-14
AU2020310538B2 (en) 2026-04-09
MX2022000252A (es) 2022-02-21
EP3997103A1 (en) 2022-05-18
CN118388588A (zh) 2024-07-26
LT3997103T (lt) 2025-02-25
KR20220032079A (ko) 2022-03-15
EP3997103B9 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
KR20230129260A (ko) 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022410422A1 (en) Carbonic anhydrase ix ligands
RU2836270C2 (ru) Соединения, содержащие лиганд белка активации фибробластов, и их применение
HK40121319A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
HK40065560A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
HK40065560B (en) Compounds comprising a fibroblast activation protein ligand and use thereof
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241218

R150 Certificate of patent or registration of utility model

Ref document number: 7608425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150